Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on Ability of Novel Monoclonal Antibodies to Boost Efficacy of DepoVax(TM)-based Cancer Immunotherapy - Market Wire 05-Apr-2017 13:05:00
Outside evidence continues to build toward critical mass. 89!!